COMPANY NEWS

3D Signatures Confirms the Status of Clinical Programs

December 4, 2018
Toronto, December 04, 2018 - 3D Signatures Inc. (TSX-V:DXD) (the “Company” or “3DS“) announces that the Board of Directors and...
Read More

3D Signatures Provides Company Update & Reinstatement to Trade

November 30, 2018
Toronto, November 30, 2018 - to the Company’s news release dated May 31, 2018, regarding an intention to assign 3D...
Read More

3D Signatures Inc. Appoints New CEO

September 25, 2018
 TORONTO, September 25, 2018 − 3D Signatures Inc. (TSX-V:DXD) (the "Company" or "3DS") is pleased to announce the appointment of...
Read More

3D Signatures Inc. To Resume Trading

September 24, 2018
TORONTO, September 24, 2018 − 3D Signatures Inc. (TSX-V:DXD) (the "Company" or "3DS") is pleased to announce that further to...
Read More

3D Signatures arranges $105K loan; CEO, CFO resign

September 17, 2018
3D SIGNATURES INC. ANNOUNCES $105,000 LOAN AND CHANGES TO ITS BOARD OF DIRECTORS AND MANAGEMENT 3D Signatures Inc. has secured...
Read More

3D SIGNATURES ANNOUNCES INTENTION TO FILE FOR BANKRUPTCY

May 31, 2018
TORONTO, May 31, 2018 3D Signa­­­­­­tures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a...
Read More

3D SIGNATURES STRENGTHENS ITS INTELLECTUAL PROPERTY WITH NEW PATENTS ISSUED FOR TESTS IN ALZHEIMER’S DISEASE, HODGKIN’S LYMPHOMA AND MULTIPLE MYELOMA

May 10, 2018
TORONTO, May 10, 2018 3D Signa­­­­­­tures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a...
Read More

3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL™ Test for Hodgkin’s Lymphoma

April 3, 2018
TORONTO, April 3, 2018 3D Signa­­­­­­tures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a...
Read More

3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer

March 28, 2018
TORONTO, March 28, 2018 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or "3DS"), a personalized medicine company with a...
Read More

3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer

March 6, 2018
TORONTO, March 06, 2018 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a...
Read More
1 2 3 9